P-Glycoprotein: Clinical Significance and Methods of Analysis

References

• Nooter K., Sonneveld P., Janssen A., et al. Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer. 1990; 45: 626–31
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., et al. Expression of mdrl and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133–40
   PubMed Web of Science ®Google Scholar
• Chin K. V., Pastan I, Gottesman M. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157–80
   PubMed Web of Science ®Google Scholar
• Chin K. V., Ueda K, Pastan I. Modulation of activity of the promoter of the human MDR1 gene by Ras and P53. Science 1992; 255: 459–62
   PubMed Web of Science ®Google Scholar
• Cornwell M. M., Schmith D. E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993; 268: 19505–11
   PubMedGoogle Scholar
• Madden M. J., Morrow C. S., Nakagawa M., et al. Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdrl gene in vivo. J Biol Chem 1993; 268: 8290–7
   PubMedGoogle Scholar
• Weinstein R. S., Kuszak J. R., Kluskens L. F., et al. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990; 21: 34–48
   PubMed Web of Science ®Google Scholar
• O'Brien J. P., Cordon-Cardo C. On the origins of clinical drug resistance. Semin Cancer Biol 1991; 2: 227–33
   Google Scholar
• Biedler J. L. Genetic aspects of multidrug resistance. Cancer 1992; 70: 1799–809
   PubMed Web of Science ®Google Scholar
• Harris A. L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992; 31: 205–13
   PubMed Web of Science ®Google Scholar
• Roninson I. B. From amplification to function: the case of the MDRl gene. Mutat Res 1992; 276: 151–61
   PubMed Web of Science ®Google Scholar
• Lum B. L., Gosland M. P., Kaubisch S., et al. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 1993; 13: 88–109
   Google Scholar
• Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Anna Rev Biochem 1993; 62: 385–427
   PubMed Web of Science ®Google Scholar
• Roninson I. B. Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 4538–42
   PubMed Web of Science ®Google Scholar
• Shen D-W, Fojo A., Chin E., et al. Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 1986; 232: 643–5
   PubMed Web of Science ®Google Scholar
• Fojo A. T., Whang-Peng J., Gottesman M. M., et al. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1985; 82: 7661–5
   PubMed Web of Science ®Google Scholar
• Roninson I. B. Detection and mapping of homologous, repeated and amplified DNA sequences by DNA renaturation in agarose gels. Nucleic Acids Res 1983; 11: 5413–31
   PubMed Web of Science ®Google Scholar
• Roninson I. B. Analysis of gene amplification by in-gel-DNA-renaturation. Gene amplification in mammalian cells. Techniques and applications, R.E. Kellems. Marcel Dekker, New York
   Google Scholar
• Sambrook J., Fritsch EF, Maniatis T. Molecular Cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989
   Google Scholar
• Riordan J. R., Deuchars K., Kartner N., et al. Amplification of P-glycoprotein genes in multidrug resistant mammalian cell lines. Nature 1985; 316: 817–9
   PubMed Web of Science ®Google Scholar
• Van der Bliek A. M., Van der Velde-Koerts T., Biedler J. L., et al. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988; 48: 5927–32
   PubMed Web of Science ®Google Scholar
• Scotto K. W., Biedler JL, Melera P. W. Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 1986; 232: 751–5
   PubMed Web of Science ®Google Scholar
• Sen S., Teeter LD, Kuo T. Specific gene amplification associated with consistent chromosomal abnormality in independently established multidrug resistant Chinese hamster ovary cells. Chromosoma 1987; 95: 117–25
   PubMedGoogle Scholar
• Gros P., Croop J, Roninson I. Isolation and characterization of DNA sequences amplified in multidrug resistant hamster cells. Proc Natl Acad Sci USA 1986; 83: 337–41
   PubMed Web of Science ®Google Scholar
• De Bruyn M. L., Van der Bliek A. M., Biedler J. L., et al. Differential amplification and disproportionate expression of five genes in three Chinese hamster lung cell lines. Mol Cell Biol 1986; 6: 4717–22
   Google Scholar
• Ito Y., Tanimoti M., Kumazawa T., et al. Increased P-glycoprotein expression and multidrug-resistant gene (mdrl) amplification are infrequently found in fresh acute leukemia cells. Cancer 1989; 63: 1534–8
   PubMed Web of Science ®Google Scholar
• Weide R., Dowding C., Paulsen W., et al. The role of the MDR-l/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia 1990; 4: 695–9
   PubMed Web of Science ®Google Scholar
• Corrias M. V., Cornaglia-Ferraris P, DiMartino D. Expression of multiple drug resistance gene, MDRl, and. N-myc oncogene in an Italian population of human neuroblastoma. Anticancer Res. 1990; 10: 897–902
   PubMedGoogle Scholar
• Shin H. J., Lee J. S., Hong W. K., et al. Study of multidrug resistance (mdrl) gene in non-small-cell-lung carcinoma. Anticancer Res 1992; 12: 367–70
   PubMed Web of Science ®Google Scholar
• Ueda K., Yamano Y., Kioka N., et al. Detection of multidrug resistance (MDRl) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. Jpn J Cancer Res 1989; 80: 1127–32
   PubMedGoogle Scholar
• Chabner B. A., Fojo A. Multidrug resistance: P-glycoprotein and its allies – the elusive foes. J Natl Cancer Inst 1989; 81: 910–3
   PubMedGoogle Scholar
• Wang A. M., Doyle MV, Mark D. F. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 9717–21
   PubMed Web of Science ®Google Scholar
• Murphy L. D., Herzog C. E., Rudick J. B., et al. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 1990; 29: 10351–6
   PubMed Web of Science ®Google Scholar
• Noonan K. E., Beck C., Holzmayer T. A., et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160–4
   PubMed Web of Science ®Google Scholar
• Sugawara I., Watanabe M., Masunaga A., et al. Primer-dependent amplification of mdrl mRNA by polymerase chain reaction. Jpn J Cancer Res 1992; 83: 131–3
   Google Scholar
• Goldstein L., Pastan I, Gottesman M. M. Quantitative detection of MDR1 RNA by PCR using a competitive RNA template. Submitted for publication 1994
   Google Scholar
• Herzog C. E., Trepel J. B., Mickley L. A., et al. Various methods of analysis of mdrl/P-gp in human cancer cell lines. J Natl Cancer Inst 1992; 84: 711–6
   PubMed Web of Science ®Google Scholar
• Kartner N., Evemden-Porelle D., Bradley G., et al. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820–3
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785–9
   PubMed Web of Science ®Google Scholar
• Meyers M. B., Rittmann-Grauer L, O'Brien J. P. Characterization of monoclonal antibodies recognizing a M, 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug resistant human tumor cells. Cancer Res 1989; 49: 3209–14
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., O'Brien J, Casals D. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8
   PubMed Web of Science ®Google Scholar
• Pearson J. W., Fogler W. E., Volker K., et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991; 1386–91
   Google Scholar
• Bak M., Efferth T., Mickisch G., et al. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 1990; 17: 72–5
   PubMedGoogle Scholar
• Arceci R. J., Stieglitz K., Bras J., et al. Monoclonal antibody to an external epitope of the human mdrl P-glycoprotein. Cancer Res 1993; 53: 310–7
   PubMed Web of Science ®Google Scholar
• Kelley D. J., Pavelic Z. P., Gapany M., et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1993; 119: 411–4
   Google Scholar
• Flynn S. D., Murren J. R., Kirby W. M., et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981–6
   PubMedGoogle Scholar
• Friedlander M. L., Bell D. R., Leary J., et al. Comparison of Western blot analysis and immuno-cytochemical detection of P-glycoprotein in multidrug resistant cells. J Clin Pathol 1989; 42: 719–22
   PubMed Web of Science ®Google Scholar
• Grogan T., Dalton W., Rybski J., et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990; 63: 815–24
   PubMed Web of Science ®Google Scholar
• van der Valk P., van Kal ken C. K., Ketelaars H., et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990; 1: 56–64
   PubMed Web of Science ®Google Scholar
• Juranka P., Zastawny R., Ling V. P-glycoprotein: MDR and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583
   PubMed Web of Science ®Google Scholar
• Barrand M. A., Twentyman P. R. Differentia] recognition of mdrla and mdrlb gene products in multidrug resistant mouse tumor cell lines by different monoclonal antibodies. Br J Cancer 1992; 65: 239–45
   Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein p170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159–64
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51: 2628–35
   PubMed Web of Science ®Google Scholar
• Scheper R. J., Bulte JWM, Brakke JGP, et al. Monoclonal antibody JSB1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 1988; 42: 389–94
   PubMed Web of Science ®Google Scholar
• Mickisch G. H., Pai L. H., Gottesmann M. M., et al. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 1992; 52: 4427–32
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–8
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., O'Brien J. P., Boccia J., et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem Cytochem 1990; 38: 1277–87
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Rybski J. A., et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747–52
   PubMed Web of Science ®Google Scholar
• Chan HSL, Thorner P. S., Haddad G., et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689–704
   PubMed Web of Science ®Google Scholar
• Verelle P., Meissonnier P, Fonck Y., et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111–6
   Google Scholar
• Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988; 263: 12163–5
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Iida H., Tsukagoshi S., et al. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730–3
   PubMed Web of Science ®Google Scholar
• Fojo A., Akiyama S., Gottesman M., et al. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 1985; 45: 3002–7
   PubMed Web of Science ®Google Scholar
• Bellamy W. T., Dalton W. S., Kailey J. M., et al. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 1988; 48: 6303–8
   Google Scholar
• Keizer H. G., Schuurhuis G. J., Broxterman H. J., et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 1989; 49: 2988–93
   PubMed Web of Science ®Google Scholar
• Ross D. D., Thompson B. W., Ordóñez J. V., et al. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometry 1989; 10: 185–91
   Google Scholar
• Schuurhuis C. M., Scheffer G. L., Scheper R. J., et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991; 64: 857–61
   PubMed Web of Science ®Google Scholar
• Wall D. M., Hu X. F., Zalcberg J. R., et al. Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator Fluo-3. J Natl Cancer Inst 1991; 83: 206–7
   PubMed Web of Science ®Google Scholar
• Dimanche-Boitrel M. T., Pelletier H., Genne P., et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 1992; 50: 677–82
   Google Scholar
• Ludesher C., Thaler J., Drach D., et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 1992; 82: 161–8
   Google Scholar
• Nooter K., Van den Engh G, Sonneveld P. Quantitative flow cytometric determination of anthracyclin content of rat bone marrow cells. Cancer Res 1983; 43: 5126–30
   Google Scholar
• Rogan A. M., Hamilton T. C., Young R. C., et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994–6
   PubMed Web of Science ®Google Scholar
• Louie K. G., Hamilton T. C., Winker M. A., et al. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 1986; 35: 467–72
   PubMed Web of Science ®Google Scholar
• Hindenburg A. A., Baker M. A., Gleyzer E., et al. Effect of verapamil and other agents on the distribution of anthracyclins and on reversal of drug resistance. Cancer Res 1987; 47: 1421–5
   PubMed Web of Science ®Google Scholar
• Fojo A. T., Ueda K., Slamon D. J., et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–9
   PubMed Web of Science ®Google Scholar
• Herweijer H., van den Engh G, Nooter K. A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry 1989; 10: 463–8
   PubMedGoogle Scholar
• Schuurhuis G. J., Broxterman H. J., Cervantes A., et al. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 1989; 81: 1887–92
   PubMed Web of Science ®Google Scholar
• Gheuens E. E., Van Bockstale D. R., Van der Keur M., et al. Flow cytometric double labeling technique for screening of multidrug resistance. Cytometry 1991; 12: 636–44
   PubMedGoogle Scholar
• Piwnica-Worms D., Chiu M. L., Budding M., et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977–84
   PubMed Web of Science ®Google Scholar
• Inaba M., Kobayashi H., Sakurai Y., et al. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P338 leukemia. Cancer Res 1979; 39: 2200–3
   PubMed Web of Science ®Google Scholar
• Bucana C. D., Giavazzi R., Nayar R., et al. Retention of vital dyes correlates inversely with the multidrug resistance phenotype of adriamycin-selected murine fibrosarcoma variants. Exp Cell Res 1990; 190: 69–75
   PubMed Web of Science ®Google Scholar
• Ludesher C., Gattringer Drach J., et al. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. Blood 1991; 78: 1385–7
   Google Scholar
• Nair S., Singh S. V., Krishan A. Flow cytometric monitoring of glutathione content and anthracycline retention in tumor cells. Cytometry 1991; 12: 336–42
   Google Scholar
• Weaver J. L., Pine P. S., Aszalos A., et al. Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug resistant cells. Exp Cell Res 1991; 196: 323–9
   PubMed Web of Science ®Google Scholar
• Hedley D. W. Flow cytometric assays of anticancer drug resistance. Ann NY Acad Sci 1993; 677: 341–53
   PubMed Web of Science ®Google Scholar
• Ludesher C., Hilbe W., Eisterer W., et al. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751–8
   Google Scholar
• Yanovich S., Preston L. Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells. Cancer Res 1984; 44: 1743–7
   Google Scholar
• Hindenburg A. A., Gervasoni J. E., Krishna S., et al. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res 1989; 49: 4607–14
   PubMed Web of Science ®Google Scholar
• Homolya L., Hollo Z., Germann U. A., et al. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993; 268: 21493–6
   PubMed Web of Science ®Google Scholar
• Willingham M. C., Cornwell M. M., Cardarelli C. O., et al. Single cell analysis and daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 1986; 46: 5941–6
   PubMed Web of Science ®Google Scholar
• Krishan A., Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res 1980; 40: 3895–900
   PubMed Web of Science ®Google Scholar
• Coley H. M., Amos W. B., Twentyman P. R., et al. Examination by laser scanning confocal imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer 1993; 67: 1316–23
   PubMed Web of Science ®Google Scholar
• De Lange J. H., Schipper N. W., Schuurhuis G. J., et al. Quantification by laser scan microscopy of intracellular doxorubicin distribution. Cytometry 1992; 13: 571–6
   Google Scholar
• Rideout D., Bustamante A., Siuzdak G. Cationic drug analysis using matrix-assisted laser desorption/ionization mass spectrometry – application to influx kinetics, multidrug resistance, and intracellular chemical change. Proc Natl Acad Sci USA 1993; 90: 10226–9
   Google Scholar
• Sugawara I., Kataoka I., Morishita Y., et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988; 48: 1926–9
   PubMed Web of Science ®Google Scholar
• Weinstein R., Jakate S. M., Dominguez J. M., et al. Relationship of the expression of the mdr gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720–6
   PubMed Web of Science ®Google Scholar
• Nooter K., Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 1991; 63: 663–9
   PubMed Web of Science ®Google Scholar
• Goldstein L. J., Galski H., Fojo A., et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–24
   PubMed Web of Science ®Google Scholar
• Pavelic Z. P., Reising J., Pavelic L., et al. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch Otolaiyngol Head Neck Surg 1993; 119: 753–7
   Google Scholar
• Isshiki K., Nakao A., Ito M., et al. P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol 1993; 52: 21–5
   Google Scholar
• Fojo A. T., Shen D., Mickley L. A., et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 1987; 5: 1922–7
   PubMed Web of Science ®Google Scholar
• Kakehi Y., Kanamaru H., Yoshida O., et al. Measurement of multidrug resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988; 139: 862–5
   PubMed Web of Science ®Google Scholar
• Kanamaru H., Kakehi Y., Yoshida O., et al. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989; 81: 844–9
   PubMed Web of Science ®Google Scholar
• Ueda K., Yamano Y., Kioka N., et al. Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. Jpn J Cancer Res 1989; 80: 1127–32
   PubMedGoogle Scholar
• Naito S., Sakamoto N., Kotoh S., et al. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur J Urol 1993; 24: 156–60
   Google Scholar
• Nishiyama K., Shirahama T., Yoshimura A., et al. Expression of multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993; 71: 3611–9
   Google Scholar
• Volm M., Kästel M., Mattern J., et al. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993; 71: 3981–7
   PubMed Web of Science ®Google Scholar
• Danova M., Giordano M, Erba E. Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer. J Cancer Res Clin Oncol 1992; 118: 575–80
   Google Scholar
• Toffoli G., Viel A., Tumiotto L., et al. Expression of the mdrl gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines. Cancer Chemother Pharmacol 1992; 29: 283–9
   Google Scholar
• Kramer R., Weber T. K., Morse B., et al. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 1993; 67: 959–68
   PubMed Web of Science ®Google Scholar
• Goldstein L. J., Fojo A. T., Ueda K., et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990; 8: 128–36
   Google Scholar
• Bourhis J., Bernard J., Hartmann O., et al. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989; 81: 1401–5261
   PubMed Web of Science ®Google Scholar
• Chan HSL, Haddad G., Thorner P. S., et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–14
   PubMed Web of Science ®Google Scholar
• Bates S. E., Shieh C. Y., Tsokos M. Expression of mdr-1 /P-glycoprotein in human neuroblastoma. Am J Pathol 1991; 139: 305–15
   Google Scholar
• Gerlach J. H., Bell D. R., Karakousis C., et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987; 5: 1452–60
   PubMed Web of Science ®Google Scholar
• Moscow J. A., Fairchild C. R., Madden M. J., et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422–8
   PubMed Web of Science ®Google Scholar
• Schneider J., Bak M., Efferth T., et al. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60: 815–8
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Grogan T. M., Miller T., et al. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989; 81: 696–701
   PubMed Web of Science ®Google Scholar
• Ro J., Sakin A., Ro J. Y., et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21: 787–91
   PubMed Web of Science ®Google Scholar
• Keith WN, Stallard S, Brown R. Expression of mdrl and gst-π in human breast tumours: comparison to in vitro sensitivity. Br J Cancer 1990; 61: 712–6
   PubMed Web of Science ®Google Scholar
• Sugawara I. Expression and function of P-glycoprotein (mndrl gene product) in normal and malignant tissues. Acta Pathol Jpn 1990; 40: 545–53
   Google Scholar
• Fuqua S. A., Fitzgerald SD, McGuire W. L. A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. Biotechniques 1990; 9: 206–11
   PubMed Web of Science ®Google Scholar
• Rubin S. C., Finstad C. L., Hoskins W. J., et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990; 163: 69–73
   PubMed Web of Science ®Google Scholar
• Rutledge M. L., Robye-Cafferty S. S., Silva E. G., et al. Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 1990; 3: 298–301
   PubMed Web of Science ®Google Scholar
• Robey-Cafferty S. S., Rutdledge ML, Bruner J. M. Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. Am J Clin Pathol 1990; 93: 1–7
   PubMedGoogle Scholar
• Benson M. C., Giella J., Whang I. S., et al. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implications and applications. J Urol 1991; 146: 982–6
   Google Scholar
• Moriyami M., Sugawar I., Hamada H., et al. Elevated expression of P-gp in kidney and urinary bladder cancers. Tohoku J Exp Med 1991; 164: 191–201
   Google Scholar
• Lai S. L., Goldstein L. J., Gottesman M. M., et al. MDRl gene expression in lung cancer. J Natl Cancer Inst 1989; 81: 1144–50
   PubMed Web of Science ®Google Scholar
• Scagliotti G. V., Michelotto F., Kalikatzaros G., et al. Detection of multidrug resistance associated P-170 glycoprotein in previously untreated non small cell lung cancer. Anticancer Res 1991; 11: 2207–10
   Google Scholar
• Shin H. J., Lee J. S., Hong W. K., et al. Study of multidrug resistance in non-small-cell lung cancer. Anticancer Res 1992; 12: 367–70
   PubMed Web of Science ®Google Scholar
• Jiang X-R, Macey M, Newland A. C. Multidrug resistance in haematological malignancies. Med LabSci 1991; 48: 261–70
   Google Scholar
• Rischin D., Ling V. Multidrug resistance in leukemia. Cancer Treat Res 1993; 64: 269–93
   Google Scholar
• Holmes J. A., Jacobs A., Carter G., et al. Is the mdrl gene expression relevant in chronic lymphocytic leukemia%. Leukemia 1990; 4: 216–8
   PubMed Web of Science ®Google Scholar
• Danuani D., Michieli M., Piled S., et al. Expression of multidrug resistance gene (MDRl) in human normal leukocytes. Haematologica 1993; 78: 12–7
   Google Scholar
• Pasman P. C., Schouten H. C. Multidrug resistance mediated by P-glycoprotein in haematological malignancies. Neth J Med 1993; 42: 218–31
   PubMedGoogle Scholar
• Rodriguez C., Commes T., Robert J., et al. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leukemia Res 1993; 17: 149–56
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Meltzer P. S., et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415–24
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Sugimoto Y., Hamada H., et al. Detection of multidrug resistance markers, P-glycoprotein and mdrl mRNA, in human leukemia cells. Jpn J Cancer Res 1987; 78: 1415–9
   PubMedGoogle Scholar
• Pirker R., Goldstein L. J., Ludwig H., et al. Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun 1989; 1: 141–5
   PubMedGoogle Scholar
• Ma DDF, Davey R. A., Harman D. H., et al. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1987; 1: 135–7
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Roninson I. B. Expression and activity of P-gp, a multidrug efflux-pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Miller T. P., Grogan T. M., Dalton W. S., et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991; 9: 17–24
   PubMed Web of Science ®Google Scholar
• Kuwazuru Y., Yoshimura A., Hanada S., et al. Expression of the multidrug transporter, P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868–73
   PubMed Web of Science ®Google Scholar
• Holmes J., Jacobs A., Carter G., et al. Multidrug resistance in haematopoietic cell lines, myelodysplasia syndromes and acute myeloblastic leukaemia. Br J Haematol 1989; 72: 40–4
   PubMed Web of Science ®Google Scholar
• Nooter K., Sonneveld P., Janssen A., et al. Overexpression of the mdrl gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporine-A. lnt J Cancer 1990; 45: 263–8
   PubMed Web of Science ®Google Scholar
• Sato H., Preisler H., Day R., et al. Mdrl transcript levels as an indicator of resistant disease in AML. Br J Haematol 1990; 75: 340–5
   PubMed Web of Science ®Google Scholar
• Sato H., Gottesman M. M., Goldstein L. J., et al. Expression of multidrug resistance gene in myeloid leukaemias. Leukemia Res 1990; 14: 11–22
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708–12
   PubMed Web of Science ®Google Scholar
• Marie J-P, Zittoun R., Sikic B. I., et al. Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–92
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute leukemia cells at diagnosis. Blood 1992; 79: 473–6
   PubMed Web of Science ®Google Scholar
• Tiirikainen M. I., Syrjala M. T., Jansson S. E., et al. Flow cytometric analysis of P-glycoprotein in normal and leukemic cells. Ann Hematol 1992; 65: 124–6
   PubMed Web of Science ®Google Scholar
• Tiirikainen M. I., Elonen E, Ruutu T. Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 1993; 50: 279–85
   PubMed Web of Science ®Google Scholar
• Rothenberg M. L., Mickley L. A., Cole D. E., et al. Expression of mdrl/P-170 gene in patients with acute lymphoblastic leukaemia. Blood 1989; 74: 1388–95
   PubMed Web of Science ®Google Scholar
• Gekeler V., Frese G., Noller A., et al. Mdrl/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 1992; 66: 507–17
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Dossot J. M., Fardel O., et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–8
   PubMed Web of Science ®Google Scholar
• Myiachim H, Takemura Y, Yonekura S. MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. Int J Hematol 1993; 57: 31–7
   Google Scholar
• Shustik C., Croulx N, Gros P. Analysis of multidrug resistance (MDR1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 1991; 79: 50–6
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H, Oba B. K. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913–7
   PubMed Web of Science ®Google Scholar
• Musto P., Lombardi G., Matera R., et al. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma. Haematologica 1991; 76: 513–6
   PubMedGoogle Scholar
• Ucci G., Petroni M., Ricardi A., et al. Expression of P 170 protein in multiple myeloma: a clinical study. Hematol Oncol 1992; 10: 213–20
   PubMed Web of Science ®Google Scholar
• Grogan T. M., Spier C. M., Salmon S. E., et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–5
   PubMed Web of Science ®Google Scholar
• Niehans G. A., Juszcz W., Brunette V., et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992; 52: 3768–75
   PubMed Web of Science ®Google Scholar
• Baines P., Cumber P, Padua R. A. Multidrug resistance in leukemia. Baillieres Clin Haematol 1992; 5: 943–60
   PubMed Web of Science ®Google Scholar
• Bellamy W. T., Dalton WS, Dorr R. T. The clinical relevance of multidrug resistance. Cancer Invest 1990; 8: 547–62
   PubMed Web of Science ®Google Scholar
• Van Kalken C. K., Pinedo HM, Giaccone G. Multidrug resistance from the clinical point of view. Eur J Cancer 1991; 27: 1481–6
   Google Scholar
• Kaye S. B. P-glycoprotein (P-gp) and drug resistance – time for reappraisal%. Br J Cancer 1993; 67: 641–3
   PubMed Web of Science ®Google Scholar
• Arceci R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215–22
   PubMed Web of Science ®Google Scholar
• Wishart G. C., Kaye S. B. Is multidrug resistance relevant in breast cancer%. Eur J Surg Oncol 1991; 17: 485–8
   Google Scholar
• Holzmayer TA, Hilsenbeck S., Von Hoff D. D., et al. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486–91
   PubMedGoogle Scholar
• Baer MR, Bloomfield C. D. Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 663–5
   PubMed Web of Science ®Google Scholar
• Nagourney R. A. Multidrug resistance i,i acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 1418–9
   Google Scholar
• Dalton W. S., Grogan T. M. Does P-gp predict response to chemotherapy, and if so, is there a reliable way to detect it%. J Natl Cancer Inst 1991; 83: 80–1
   PubMed Web of Science ®Google Scholar
• Hart S. M., Ganeshaguru K., Lyltelton M. P., et al. Flow cytometrical assessement of multidrug resistance (MDR) phenotype in acute myeloid leukaemia. Leukemia Lymphoma 1993; 11: 239–48
   PubMed Web of Science ®Google Scholar
• Murren J. R., Hait W. N. Why haven't we cured multidrug resistant tumors%. Oncol Res 1992; 4: 1–6
   PubMed Web of Science ®Google Scholar